Clinical Trial

A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and Above

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated March 27, 2026 (before its estimated July 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to assess the reactogenicity, safety and immune response of GlaxoSmithKline's (GSK) messenger RNA (mRNA)-based multivalent seasonal influenza vaccine candidates administered in healthy younger and older adults.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-10-01; most recent amendment 2026-03-23.
Status change: Recruiting → Active, Not Recruiting 2026-03-23
Status change: Not Yet Recruiting → Recruiting 2025-11-28
Trial Details
NCT Number NCT07204964
Lead Sponsor GlaxoSmithKline
Conditions Influenza, Human
Enrollment 971 participants
Start Date 2025-10-07
Primary Completion 2026-07-31 (estimated)
Study Completion 2026-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-27